In her last week at AdExchanger, Senior Editor Alyssa Boyle reflects on three years of change, and stasis, in the CTV space.

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

By Adrianne Pasquarelli - 1 hour 33 min ago By Tim Nudd - 2 hours 53 min ago By Tom Wormald - 5 hours 33 min ago 5 hours 33 min ago By Andre Banks - 6 hours 3 min ago By Ad Age Staff - 8 months 1 ...

The Food and Drug Administration said Friday the shortage of Ozempic and Wegovy is over ... The company promoted its ...

“Novo Nordisk is warning consumers about the significant dangers of reaching for illegitimate compounded ‘semaglutide’ drugs, which have been shown to contain impurities and ingredients ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...

Ozempic and Wegovy, the widely popular forms of semaglutide ... The online company advertised its sale of compounded GLP-1 ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

reads text in the print ad, above a needle and vial labeled compounded semaglutide. “Bottom line: If the label doesn’t say Wegovy® (semaglutide) or Ozempic® (semaglutide), it’s not FDA ...

penned a letter to the FDA in which they teased upcoming bipartisan legislation relevant to the ad. “We recognize the ... semaglutide medicines (Wegovy, Ozempic, and Rybelsus), patient safety ...